Sign In
Buy ACRX
$0.86
+0 (+0%)
At Close: Apr 08, 2024
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 10'th May 2023
Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webc
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
08:30am, Wednesday, 05'th Apr 2023
In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. ,
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
10:15pm, Thursday, 30'th Mar 2023 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
08:28pm, Thursday, 30'th Mar 2023
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Of
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
08:01pm, Thursday, 30'th Mar 2023
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
04:05pm, Thursday, 30'th Mar 2023
Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
04:05pm, Tuesday, 21'st Mar 2023
HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript
11:09pm, Monday, 14'th Nov 2022
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
10:15pm, Monday, 14'th Nov 2022 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
What Happened This Week: Twitter, Tech Wreck And Apple – Earnings Week To Remember
08:45pm, Friday, 28'th Oct 2022 Investing.com
Why Skechers Shares Are Trading Lower; Here Are 25 Stocks Moving Premarket
10:18am, Wednesday, 26'th Oct 2022 Benzinga
Gainers
Ensysce Biosciences, Inc. (NASDAQ: ENSC) rose 53.5% to $0.32 in pre-market trading after gaining 13% on Tuesday.
Cosmos Holdings Inc. (NASDAQ: COSM) shares rose 22.7% to $0.1071 in pre-market
Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket
10:30am, Monday, 17'th Oct 2022 Benzinga
Gainers
Inpixon (NASDAQ: INPX) shares rose 56.7% to $7.49 in pre-market trading after gaining around 10% on Friday. Inpixon reported recent purchase orders of industrial IoT solutions supporting a va
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
10:55am, Thursday, 29'th Sep 2022 Benzinga
Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European
Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket
10:16am, Wednesday, 21'st Sep 2022 Benzinga
Gainers
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday.
AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 14.2% to $
